Valneva (NASDAQ:VALN – Get Free Report) is projected to announce its Q3 2026 results before the market opens on Tuesday, November 24th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $43.67 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 24, 2026 at 9:00 AM ET.
Valneva Stock Down 0.2%
Shares of NASDAQ VALN opened at $5.65 on Tuesday. Valneva has a 12 month low of $4.75 and a 12 month high of $12.18. The firm has a market capitalization of $537.82 million, a PE ratio of -2.68 and a beta of 1.37. The firm has a fifty day simple moving average of $5.94 and a two-hundred day simple moving average of $6.64. The company has a current ratio of 2.16, a quick ratio of 1.69 and a debt-to-equity ratio of 2.04.
Wall Street Analysts Forecast Growth
Several brokerages have recently issued reports on VALN. Weiss Ratings raised Valneva from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, November 10th. TD Cowen started coverage on shares of Valneva in a report on Tuesday, August 11th. They issued a “buy” rating and a $12.00 target price for the company. One research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Valneva has an average rating of “Reduce” and a consensus target price of $9.30.
About Valneva
Valneva is a specialty vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases. Founded in 2013 through the combination of Vivalis and Intercell, the company is headquartered in Saint-Herblain, France, and serves markets in Europe, North America and other regions through direct operations and commercial partners. Its marketed vaccines include IXIARO, for prevention of Japanese encephalitis, and DUKORAL, an oral vaccine for cholera. Valneva also developed IXCHIQ, a vaccine to prevent disease caused by chikungunya virus, which has received regulatory authorization in the United States and Europe.
See Also
- Five stocks we like better than Valneva
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.
